Form 10-K for Macrogenics INC filed 03/15/2023 - Annual Reports

A bi-specific mAb that targets LAG-3 and PD-1, known as tebotelimab, has been evaluated, alone or combined with margetuximab, for various ...

Autres Cours:

The global leader in developing LAG-3 therapeutics - Immutep

Immune checkpoint inhibitors and SARS-CoV2 infection

no28.pdf - ??????

?????????????2018 ????? - ???????

'24 ? 7 ? ????????? ????

? ? ? ? ? - ???????? ????????

???? - ???

???????? Vol. 26 No. 2 2011

?????????

?????????????? ?? 54 ??????????

???????? U-ENG23 22051 LJ55 - ????? - ????

??? https://www.jv-campus.org/ https://www.jv-campus.org/user ...